-
Posted by
Two Blokes Jun 12 -
Filed in
Stock
-
18 views
Delcath's HEPZATO shows rapid sales growth and high pricing, but its efficacy is only moderately better than alternatives and not curative. The addressable market is small, treatment is complex, and future competition from Replimune or Ideaya could threaten long-term prospects and valuation multiples. Financials are solid with no debt, recent profitability, and reasonable stock-based compensation; forward P/S ratio is attractive versus peers.
